120,927 Shares in AnaptysBio, Inc. $ANAB Acquired by Eversept Partners LP

Eversept Partners LP acquired a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) in the 4th quarter, HoldingsChannel reports. The fund acquired 120,927 shares of the biotechnology company’s stock, valued at approximately $5,863,000.

Other institutional investors also recently bought and sold shares of the company. 683 Capital Management LLC boosted its stake in shares of AnaptysBio by 18.5% in the fourth quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company’s stock valued at $31,420,000 after purchasing an additional 101,093 shares during the period. Schonfeld Strategic Advisors LLC bought a new position in AnaptysBio during the 4th quarter valued at $1,184,000. Jump Financial LLC boosted its stake in AnaptysBio by 46.5% during the 4th quarter. Jump Financial LLC now owns 120,217 shares of the biotechnology company’s stock valued at $5,828,000 after acquiring an additional 38,140 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of AnaptysBio by 1,427.4% during the fourth quarter. Osaic Holdings Inc. now owns 27,737 shares of the biotechnology company’s stock worth $1,344,000 after purchasing an additional 25,921 shares during the period. Finally, State of Wisconsin Investment Board acquired a new stake in shares of AnaptysBio during the fourth quarter worth $434,000.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Weiss Ratings lowered AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Leerink Partners set a $90.00 target price on shares of AnaptysBio in a research note on Friday, May 15th. Zacks Research cut shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Wedbush raised their target price on shares of AnaptysBio from $60.00 to $75.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Finally, Wall Street Zen cut shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $81.82.

AnaptysBio Price Performance

Shares of ANAB opened at $56.77 on Thursday. The firm’s 50 day moving average is $60.26 and its 200-day moving average is $54.84. The stock has a market capitalization of $1.65 billion, a P/E ratio of -52.56 and a beta of 0.72. AnaptysBio, Inc. has a 12-month low of $11.40 and a 12-month high of $72.36.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($1.20). The firm had revenue of $25.56 million during the quarter, compared to analysts’ expectations of $18.86 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 11.53%. As a group, equities research analysts forecast that AnaptysBio, Inc. will post -1.35 EPS for the current fiscal year.

AnaptysBio declared that its board has authorized a stock repurchase program on Friday, March 27th that permits the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization permits the biotechnology company to purchase up to 5,352,316.2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity at AnaptysBio

In other news, CEO Daniel Faga sold 17,679 shares of AnaptysBio stock in a transaction that occurred on Friday, March 27th. The shares were sold at an average price of $61.61, for a total value of $1,089,203.19. Following the transaction, the chief executive officer directly owned 495,965 shares of the company’s stock, valued at $30,556,403.65. This trade represents a 3.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John P. Schmid sold 20,645 shares of AnaptysBio stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $56.11, for a total transaction of $1,158,390.95. Following the completion of the transaction, the director directly owned 31,622 shares in the company, valued at approximately $1,774,310.42. This trade represents a 39.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 33.50% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.